OncoTargets and Therapy (Apr 2020)

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights

  • Starr JS,
  • Sonbol MB,
  • Hobday TJ,
  • Sharma A,
  • Kendi AT,
  • Halfdanarson TR

Journal volume & issue
Vol. Volume 13
pp. 3545 – 3555

Abstract

Read online

Jason S Starr,1 Mohamad Bassam Sonbol,2 Timothy J Hobday,3 Akash Sharma,4 Ayse Tuba Kendi,3 Thorvardur R Halfdanarson3 1Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA; 2Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA; 3Division of Hematology/Oncology, Mayo Clinic, Rochester, MN, USA; 4Division of Nuclear Medicine, Mayo Clinic, Jacksonville, FL, USACorrespondence: Jason S StarrMayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USAEmail [email protected]: Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the treatment of neuroendocrine tumors. Although there are no prospective randomized trials directly studying PRRT in pancreatic neuroendocrine tumors (panNETs), there are data to suggest benefit in this patient population. Collectively, the data, consisting of two prospective and six retrospective studies, show a median PFS ranging from 20 to 39 months and a median OS ranging from 37 to 79 months. There are ongoing (and upcoming) prospective, randomized trials of PRRT in panNETs, which will provide further evidence to support this approach.Keywords: pancreatic neuroendocrine tumor, panNET, peptide receptor radionuclide therapy, PRRT, theranostics

Keywords